التفاصيل البيبلوغرافية
| العنوان: |
Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. |
| المؤلفون: |
Allou, Nicolas, Bouteau, Astrid, Allyn, Jérôme, Snauwaert, Aurélie, Valance, Dorothée, Jabot, Julien, Bouchet, Bruno, Galliot, Richard, Corradi, Laure, Montravers, Philippe, Augustin, Pascal |
| المصدر: |
Annals of Intensive Care; 11/2/2016, Vol. 6 Issue 1, p1-8, 8p |
| مصطلحات موضوعية: |
MOLECULAR structure of aminoglycosides, SEPTIC shock treatment, ANTI-infective agents, AMIKACIN, AMINOGLYCOSIDES |
| مستخلص: |
Background: The therapeutic effect of aminoglycosides is highest and optimal when the peak plasma concentration ( C )/minimal inhibitory concentration (MIC) ratio is between 8 and 10. The French guidelines recommend to use high doses of aminoglycosides for empiric antibiotic therapy in patients suffering from severe sepsis or septic shock. In clinical practice, the recommended target is an amikacin C between 60 and 80 mg/L, which corresponds to approximately 8 times the MIC breakpoint, as defined by the European Committee on Antimicrobial Susceptibility Testing. The aim of this study was to assess the incidence and impact on mortality of an amikacin concentration between 60 and 80 mg/L in patients suffering from severe sepsis or septic shock. Methods: This was a prospective observational cohort study conducted in two intensive care units (ICU). Patients receiving amikacin at a loading dose of 30 mg/kg for severe sepsis or septic shock were enrolled in the cohort. The target C for amikacin was between 60 and 80 mg/L, as recommended by French guidelines (i.e. C /MIC breakpoint = 8-10). Results: Over the study period, the amikacin C was <60 mg/L, between 60 and 80 mg/L, and >80 mg/L in 20 (18.2%), 46 (41.8%) and 44 (40%) of the 110 selected patients, respectively. Mortality rate was 40, 28.3 and 56.8% in the groups of patients with C < 60 mg/L, 60 mg/L < C < 80 mg/L and C > 80 mg/L, respectively. Following multivariate analysis, mortality rate was significantly lower in the group of patients with amikacin C between 60 and 80 mg/L than in the group of patients with amikacin C > 80 mg/L ( P = 0.004). The multivariate analysis also revealed that the factors independently associated with a higher in-ICU mortality rate were age ( P = 0.02) and norepinephrine dose ( P = 0.0001). Conclusions: With a loading dose of 30 mg/kg of amikacin, concentration was potentially suboptimal ( C < 60 mg/L) in only 18.2% of patients. The pharmacodynamic target (60 mg/L < C < 80 mg/L) recommended by French guidelines was reached in 41.8% of patients and was associated with reduced in-ICU mortality. But amikacin overexposure (i.e. C > 80 mg/L) was frequent and potentially associated with increased mortality. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Intensive Care is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder